{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:00:53Z","timestamp":1768071653758,"version":"3.49.0"},"reference-count":18,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Mast cells (MCs) have been implicated in a spectrum of allergic, immunologic, and infectious inflammatory conditions that involve different organ systems. MC activation can occur through several different surface receptors other than the well known IgE mediated pathway.<jats:bold>Methods:<\/jats:bold>We use two representative case reports from our practice to summarize what is currently known about MCAS disorders (reality) so that the clinician can more easily differentiate these conditions from other complex unexplained conditions that are being associated with MC activation (myth).<jats:bold>Results:<\/jats:bold>Many complex MC-related conditions, such as clonal MC diseases, have been well characterized but other MC-related disorders, such as MC activation syndrome (MCAS) and idiopathic anaphylaxis, still remain poorly defined. The current consensus recommendations for a diagnosis of MCAS require clinical symptoms of anaphylaxis that correlate with elevation of a MC activation biomarker(s), which improves with H1-antihistamines.<jats:bold>Conclusion:<\/jats:bold>Clinical symptoms of MCAS can overlap with other conditions, including neurogenic disorders, e.g., dysautonomia, which necessitate the importance for the clinician to render an accurate diagnosis so that appropriate treatment is provided.<\/jats:p>","DOI":"10.2500\/aap.2021.42.210012","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T10:11:09Z","timestamp":1620900669000},"page":"198-204","source":"Crossref","is-referenced-by-count":8,"title":["Mast cell activation syndrome: Myths and realities"],"prefix":"10.2500","volume":"42","author":[{"given":"Simin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1615\/CritRevImmunol.v31.i6.30","article-title":"Regulation of mast cell responses in health and disease","volume":"31","author":"Gilfillan","year":"2011","journal-title":"Crit Rev Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"e89362","DOI":"10.1172\/jci.insight.89362","article-title":"Dual action of neurokinin-1 antagonists on Mas-related GPCRs","volume":"1","author":"Azimi","year":"2016","journal-title":"JCI Insight"},{"key":"B3","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2500\/aap.2020.41.190023","article-title":"Mast cell disorders and idiopathic anaphylaxis: evaluation and management","volume":"41","author":"Khalid","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"B10","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pcad.2020.03.010","article-title":"Postural orthostatic tachycardia syndrome (POTS): a critical assessment","volume":"63","author":"Olshansky","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"B12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12016-019-08755-8","article-title":"The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS)","volume":"58","author":"Kohn","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1081-1206(10)61484-6"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2500\/ajra.2014.28.4059","article-title":"Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis","volume":"28","author":"Singh","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.mehy.2011.07.024","article-title":"Hypofunction of the sympathetic nervous system is an etiologic factor for a wide variety of chronic treatment-refractory pathologic disorders which all respond to therapy with sympathomimetic amines","volume":"77","author":"Check","year":"2011","journal-title":"Med Hypotheses"},{"key":"B18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000158259.68614.40","article-title":"Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders","volume":"45","author":"Shibao","year":"2005","journal-title":"Hypertension"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2021\/00000042\/00000003\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T17:57:57Z","timestamp":1699034277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2021.42.210012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,1]]}},"alternative-id":["1088-5412(20210501)42:3L.198;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2021.42.210012","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}